ERBB2 and breast cancer: Dual-targeting different regions and overcoming steric hindrance of HER2 in IHC detection through the Nby-Aby fusion protein enhances diagnostic sensitivity, providing a novel strategy for more accurate HER2 IHC assessment in BC diagnosis.